Mark J Foley
CIK 1529196 · President & CEO · last filed 2026-06-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.78M
Companies
4
Total Filings
121
Lifetime Open-Market Net
-$30.04M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GKOS | Director | 60,267 | $126.81 | $7.64M | -$2.92M | 18 | 2026-06-01 |
| Revance Therapeutics, Inc. (RVNC) Delisted | President & CEO | 27,933 | $3.65 | $102.0K | -$5.60M | 34 | 2025-02-06 |
| SIBN | Director | 8,797 | $15.42 | $135.6K | $0 | 2 | 2020-06-18 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | President and CEO | 0 | — | — | -$21.52M | 67 | 2017-04-28 |
Recent Filings · Page 3 of 13
121 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-16 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +105,202 | -$2.43M | EDGAR |
| 2023-03-17 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −5,341 | -$163.7K | EDGAR |
| 2023-03-09 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +105,259 | -$2.22M | EDGAR |
| 2023-01-04 | GKOS | Grant (A) | +2,948 | $0 | EDGAR |
| 2023-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +605 | $7.4K | EDGAR |
| 2022-10-14 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −49,274 | -$1.33M | EDGAR |
| 2022-07-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +1,000 | $11.7K | EDGAR |
| 2022-06-06 | GKOS | Grant (A) | +4,364 | $0 | EDGAR |
| 2022-03-17 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −3,304 | -$52.2K | EDGAR |
| 2022-02-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.